Prices are updated after-hours

Biora Therapeutics Inc

BIOR | $0.6156 2.69% 2.62% 100K

(0.0% 1d) (-48.7% 1m) (-76.3% 1y) (0.0% 2d) (0.0% 3d) (-1.6% 7d) (-56.7% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 22,090,094
https://www.progenity.com
Sec Filling | Patents | 642 employees

(US) Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

treatment diagnostics

add to watch list Paper trade email alert is off

Press-releases

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -15.8% | O: -2.0% H: 2.61% C: 2.21%
patent technology therapeutics

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -17.58% | O: 1.34% H: 0.0% C: -4.21%
bt-600 positive trial therapeutics results platform

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2024-04-03 (Crawled : 20:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -17.58% | O: 1.34% H: 0.0% C: -4.21%
nasdaq million direct offering therapeutics

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -44.55% | O: -27.7% H: 3.03% C: -7.54%
nasdaq million direct offering therapeutics

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Published: 2024-03-26 (Crawled : 20:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -54.14% | O: -7.52% H: 0.0% C: -4.88%
update therapeutics financial results

Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -45.54% | O: 0.89% H: 4.42% C: 1.77%
report year update therapeutics financial results

Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
Published: 2024-03-11 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -48.74% | O: 8.4% H: 1.55% C: -1.55%
therapeutics